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Abstract
Background Few works have evaluated the effect of statins
on left ventricular dysfunction in patients with chronic heart
failure (CHF), by using tissue Doppler imaging (TDI). We
therefore aimed to investigate whether atorvastatin treatment
may influence prognosis and myocardial performance eval-
uated by TDI in subjects with CHF.
Methods Five hundred thirty-two consecutive CHF outpa-
tients enrolled in a local registry, the Daunia Heart Failure
Registry, were prospectively analysed. 195 patients with
CHF and left ventricular ejection fraction (LVEF) ≤40 %,
either in treatment with atorvastatin (N: 114) or without
statins (N: 81), underwent TDI examination. Adverse events
were evaluated during follow-up.
Results The atorvastatin group showed a lower incidence of
adverse events (cardiac death: 0 % vs 7 %, p<0.01), and
better TDI performance (E/E’ 15±5.7 vs 18±8.3, p<001)
than controls. Ischaemic CHF patients in treatment with
atorvastatin also showed a lower incidence of adverse events
(death: 10 % vs 26 %, p<0.05; sustained ventricular ar-
rhythmias: 5 % vs 19 %, p<0.05, cardiac death: 0 vs 8 %,
p<0.05) and better TDI performance (E/E’ ratio: 15.00±
5.68 vs 19.72±9.14, p<0.01; St: 353.70±48.96 vs 303.33±
68.52 msec, p<0.01) than controls. The association between
atorvastatin and lower rates of cardiac death remained sta-
tistically significant even after correction in a multivariable
analysis (RR 0.83, 95 % CI 0.71–0.96, p<0.05 in CHF with
LVEF ≤40 %; RR 0.77, 95 % CI 0.62–0.95, p<0.05 in
ischaemic CHF with LVEF ≤40 %).
Conclusions Treatment with atorvastatin in outpatients with
systolic CHF is associated with fewer cardiac deaths, and a
better left ventricular performance, as assessed by TDI.
Keywords Chronic heart failure . Atorvastatin .
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Introduction
Chronic heart failure (CHF) is characterised by an impaired
systolic and diastolic function and an inflammatory
activation.
Left ventricular (LV) performance may be assessed with
several methods: Tissue Doppler imaging (TDI) is an opti-
mal echocardiographic tool for quantitative assessment of
LV systolic and diastolic function. TDI can be used to
measure systolic time (St) and ejection time (ET) intervals
in a noninvasive, geometrically independent, easily applica-
ble fashion [1, 2]. Few authors, however, have evaluated
these intervals in CHF patients [3, 4].
Observational studies [5–7], prospective studies [8–12],
and post-hoc analyses [13–16] of randomised clinical trials
have suggested that statins could be beneficial in patients
with CHF. The mechanisms of possible beneficial effects of
statin administration in CHF patients are not completely
known. Small prospective clinical studies with atorvastatin
and simvastatin in systolic HF have documented an im-
proved LV systolic function and decreased inflammatory
biomarkers levels after statin therapy [17].
Few works, however, have evaluated the effect of statin
therapy on LV dysfunction in patients with CHF, particular-
ly using TDI [18]. We therefore aimed to investigate wheth-
er atorvastatin administration may influence prognosis and
myocardial performance evaluated by TDI in subjects with
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CHF enrolled in a local registry of patients with CHF: the
Daunia Heart Failure Registry.
Methods
Between 1 January 2009 and 1 January 2012, a total of 532
consecutive outpatients with CHF were enrolled in the
Daunia Heart Failure Registry [19]. We prospectively
analysed 195 outpatients with CHF and left ventricular
ejection fraction (LVEF) ≤40 % either on treatment with
atorvastatin (N: 114) or without statins (N: 81); their
clinical characteristics are given in Table 1. Medical his-
tory, heart rate, systolic blood pressure, body mass index,
New York Heart Association class, and medications were
recorded. All patients underwent conventional 2D and TDI
Table 1 Clinical characteristics
of CHF with LVEF ≤40 %
(atorvastatin group vs controls)
Atorvastatin Controls P
Age (years) 66.39±10.026 60.36±14.949 0.000926
Male (%) 80 83 0.614004
BMI kg/m2 29.23±4.534 28.82±4.868 0.574937
weight (Kg) 76.89±13.706 79.07±18.209 0.369687
Height (cm) 162.68±9.149 165.30±10.164 0.081052
HR (bpm) 75.48±15.194 81.05±18.568 0.024752
SBP(mmHg) 121.14±23.644 116.30±22.071 0.158772
Ischaemic heart disease (%) 61 33 0.000180
Hypertension (%) 71 39 0.000011
COPD(%) 56 46 0.147249
Diabetes(%) 25 23 0.675104
Chronic kidney failure(%) 38 28 0.136508
Creatinine 1.57±0.463 1.41±0.540 0.136997
III-IV NYHA (%) 70 77 0.249199
AICD/CRT-D(%) 41 38 0.862190
Ivabradine (%) 6 2 0.230706
ACE-/ARB (%) 82 72 0.316212
Beta-blockers (%) 93 85 0.077681
Digoxin (%) 10 17 0.128924
Diuretics (%) 95 85 0.023130
NT-pro-BNP (pg/ml) 1413.63±1478.539 2124.88±3122.134 0.018
CRP (mg/dl) 3.57±4.102 9.68±14.015 0.000000
LVEF(%) 29.61±6.59 28.11±6.43 0.116897
LVEDD (mm) 62.71±9.453 66.04±9.920 0.019201
LVESD (mm) 53.57±12.089 56.63±9.983 0.141467
E (cm/s) 82.23±32.838 97.66±34.572 0.003651
A (cm/s) 81.60±26.477 74.63±33.520 0.193353
E/A 1.76±0.870 2.20±0.888 0.001352
EDT (ms) 203.64±95.741 173.68±83.218 0.041187
E/E’ 14.91±5.779 18.23±8.367 0.003135
S (cm/s) 8.09±2.7332 4.79±1.365 0.322023
E’ (cm/s) 6.50±3.173 6.08±2.840 0.379821
Peak VO2 (ml/kg/m) 12.58±3.500 12.63±3.895 0.58
%AT 36.93 32.81 0.690214
VO2/WR slope 10.74±1.526 10.93±2.386 0.044
O2 pulse % 76.42 58.00 0.003820
RER 1.05±0.127 1.08±0.081 0.378357
VE/VCO2 slope 30.76±6.304 32.92±6.183 0.281642
Watts 63.45±26.204 61.78±19.598 0.813435
6MWT (m) 301.60±106.051 314.80±90.320 0.837493
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echocardiography in the ambulatory setting and under rest-
ing conditions. Clinical follow-up was performed every
6 months for a mean 318±262 days follow-up. Clinical
follow-up was anticipated in case of worsening
decompensated HF. Patients were then analysed according
to the presence of coronary heart disease (patients with a
history of previous myocardial infarction, known coronary
artery disease, prior percutaneous coronary interventions
(PCI) and coronary artery bypass grafting (CABG)).
Incidence of major adverse cardiac events (cardiac death,
readmission for HF and ventricular arrhythmias) was eval-
uated by direct clinical examination or by direct interroga-
tion of a next of a kin. Cardiac death was considered if death
occurred suddenly or was associated with documented myo-
cardial infarction, congestive HF and malignant ventricular
arrhythmias.
All patients gave written informed consent. The study
was approved by the local ethics committee and was
conducted according the ethical standards for experiments
in human subjects established by the Declaration of
Helsinki.
Echocardiography
Conventional echocardiography was used to assess LV di-
mensions and ejection fraction (EF), peak velocities of
trans-mitral early (E) and late diastolic (A) LV filling, the
ratio of trans-mitral early to late (E/A ratio) LV filling
velocity, and E-deceleration time (EDT). TDI measurements
recorded at the mitral annulus in apical four-chamber view
included systolic velocity (S’), early (E’) and late (A’)
diastolic velocities, the ratio of early to late diastolic veloc-
ity (E’/A’). The trans-mitral to mitral annular early diastolic
velocity ratio (E/E’) was calculated.
ICT (ICT: end of A’wave to start of S), ET (start of S wave
to end of S wave), St (end of A’ wave to end of S wave), IRT
(IRT: end of S wave to start of E’), FT (start of E’ to end of A’),
ICT/ET and MPI (Myocardial Performance Index: [ICT +
IRT)/ET] were also calculated by TDI (Fig. 1).
Transthoracic echocardiography was performed with the
use of iE33 (Philips Medical Systems, Andover, MA, USA).
All echocardiographic studies were performed and interpreted
by experienced physicians. LV dimensions and LVEF were
calculated according to the recommendations in the combined
American Society of Echocardiography/European Society of
Cardiology guidelines. LVEF was calculated according to
Simpson’s rule. Pulsed Doppler mitral inflow velocities were
obtained by placing a 1–2 mm sample volume between the
tips of the mitral leaflets in the apical four-chamber view. The
Doppler beam was aligned parallel to direction of flow.
TDI was performed using apical views for the long-axis
motion of the ventricles as previously described [20]. Two-
dimension echocardiography with TDI colour imaging was
performed with an S5-1 Sector Array Transducer with
PureWave Crystal Technology (5 to 1 MHz). Two-
dimensional echocardiography with TDI colour imaging
views was optimised for pulse repetition frequency, colour
saturation, sector size, and depth and was allowed the
highest possible frame rate. At least three consecutive beats
were stored, and the images were analysed offline with the
aid of a customised software package (QLAB quantification
software, Philips).
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation, categorical variables were presented as percent-
ages. Mean values were compared with Student’s t-test for
variables with a normal distribution or with the Mann–
Whitney non-parametric U test for variables with a non-
normal distribution. Percentages were compared with the
χ2 test. Event-free survival was shown with Kaplan-Maier
curves and compared with the log-rank test. Univariate re-
sults were corrected in a multivariate analysis for age, gen-
der and LVEF and other significant factors. A p<0.05 was
considered to be statistically significant.
Fig. 1 TDI measurements recorded at the septal mitral annulus in the
apical four-chamber view: ICT (ICT: end of A’ wave to start of S), ET
(start of S wave to end of S wave), St (end of A’ wave to end of S
wave), IRT (IRT: end of S wave to start of E’), FT (start of E’ to end of
A’) and MPI (Myocardial Performance Index: [ICT + IRT)/ET] were
calculated by TDI
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Results
We prospectively analysed 195 outpatients with CHF and
LVEF ≤40 %; in these patients, atorvastatin therapy was
associated with a lower incidence of cardiac death (0 % vs
7 %, p<0.01) than in controls. The association remained
statistically significant even after correction in a multivari-
able analysis for age, gender, LVEF, ACE-inhibitors and
beta-blocker therapy (RR 0.83, 95 % CI 0.71–0.96, p<
0.05 in CHF with LVEF ≤40 %) (Fig. 2).
Patients treated with atorvastatin were characterised by
lower values of E (82.23±32.8 cm/sec vs 97.6±34.5 cm/sec,
p: 0.01), E/A ratio (1.7±0.8 vs 2.2±0.8, p<0.001) and E/E’
ratio (15±5.7 vs 18±8.3, p<0.01) and higher values of EDT
(203.6±95.7 ms vs 173.6±83.2 ms, p<0.05) (Table 1).
Ischaemic CHF patients with LVEF ≤40 % on treatment
with atorvastatin also showed a lower incidence of adverse
events (death: 10 % vs 26 %, p<0.05; sustained ventricular
arrhythmias: 5 % vs 19 %, p<0.05, cardiac death: 0 vs 8 %,
p<0.05) and better Doppler findings, as lower values of
E/E’ ratio (15.00±5.68 vs 19.72±9.14, p<0.01), E/A ratio
(1.85±0.90 vs 2.,48±0.82, p<: 0.01), higher values of St:
353.70±48.96 vs 303.33±68.52 msec, p<0.01) than con-
trols. The association between atorvastatin and lower rates
of cardiac death in this group remained statistically signifi-
cant even after correction in a multivariable analysis for age,
gender, LVEF, ACE-inhibitor and beta-blocker therapy (RR
0.77, 95 %-CI 0.62–0.95, p<0.05 in ischaemic CHF with
LVEF ≤40 %) (Fig. 3). Kaplan-Maier survival analysis
showed higher rates of cardiac death in subjects not
receiving therapy with atorvastatin (log rank p<0.01)
(Fig. 4).
Ischaemic CHF outpatients in treatment with atorvastatin
(N: 137), showed longer systolic and diastolic time inter-
vals: (IRT: 124.06±49.23 vs 86.35±32.87 ms, p<0.01; St:
354.00±44.82 vs 322.18±62.54 ms, p<0.05; FT: 379.,37±
121.08 vs 317.94±87.61, p<0.05; Dt: 503.43±131.94 vs
404.29±89.82, p<0.01) than controls (N: 44). (Table 2).
Discussion
Chronic heart failure is a major healthcare problem associ-
ated with high morbidity and mortality. Despite significant
progress in treatment strategies, the prognosis of heart fail-
ure patients remains poor [21]. Several observational studies
on HF cohorts have linked statin therapy with an improved
survival [10–15]. The current available evidence suggests
that statins work just as well in women as in men, for
preventing both heart attacks and strokes [22].
Previous evidence shows that, in patients with prior myo-
cardial infarction, statin therapy initiated before hospital
discharge significantly reduces subsequent hospitalisations
for HF [23, 24]; initiation and maintenance of treatment
with statins is associated with better survival in patients with
LV systolic dysfunction [25] and a significant reduction in
cardiac morbidity [26]. However, the mechanisms of possi-
ble beneficial effects are not completely understood.
Fig. 2 Multivariable analysis
for age, gender, LVEF, ACE-
inhibitors and beta-blockers
therapy in CHF patients with
LVEF ≤40 % (ischaemic and
non aetiology)
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Krum et al. [13] retrospectively analysed the Valsartan
Heart Failure Trial (Val-HeFT) database to determine out-
comes in CHF patients with mild to moderate systolic chronic
heart failure according to statin use at baseline, and they
showed that mortality over a mean 2-year follow-up was
17.9 % on statins versus 20.3 % without statins (p=0.029).
Even if these findings suggest a prognostic benefit for statins
in established CHF, prospective data were required to defini-
tively address this issue.
Small prospective clinical studies on atorvastatin and
simvastatin in systolic HF documented an improved
ventricular systolic function and decreased levels of inflam-
matory biomarkers after statin therapy [27].
In a previous paper, Sankaranarayanan et al. [28] showed
that mortality in patients with ischaemic CHF treated with
statins was significantly lower than in controls. Univariate
analysis also showed fewer HF readmissions (7 % vs 32 %)
and HF deaths (4 % vs 13 %), with effects independent of
cholesterol levels, age, sex, drugs, revascularisation, and im-
plantable cardioverter-defibrillator or cardiac resynchronisation
therapy at multivariable analysis. Our study results seem to
confirm this prior evidence; therapy with atorvastatin was
Fig. 3 Multivariable analysis
for age, gender, LVEF,
ACE-inhibitors and beta-
blockers therapy in ischemic
CHF patients with LVEF ≤40 %
Fig. 4 Kaplan-Maier survival
analysis showed higher rates of
cardiac death in subjects not
receiving therapy with
atorvastatin (log rank p<0.01)
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associated with a lower incidence of cardiac death, and associ-
ation remained statistically significant even after correction in a
multivariable analysis. Furthermore, ischaemic HF patients
receiving therapy with atorvastatin showed a lower incidence
of death, cardiac death and sustained ventricular arrhythmias.
However, randomised controlled trials (Controlled Rosuvastatin
Multinational Trial in Heart Failure [CORONA] [29] and
The Gruppo Italiano per lo Studio della Sopravvivenza
nell’Insufficienza cardiaca Heart Failure [GISSI-HF]) [30] led
to different findings. In both studies, 10 mg rosuvastatin re-
duced blood cholesterol and inflammatory parameters without
any effect on mortality. According to a recent meta-analysis by
Zhang et al. [31] on 13 trials involving 10,447 chronic HF
patients, a potential explanation for this discrepancy could be
hypothesised in the different lipophilicity and hydrophilicity
among statins. The lipophilic simvastatin and atorvastat-
in had a higher uptake in cardiac tissue than the hydrophilic
rosuvastatin. The greater uptake of lipophilic statins by the
Table 2 Clinical characteristics
of ischaemic CHF (atorvastatin
group vs controls)
Atorvastatin Controls p
Age (years) 66.95±9.82 70.18±11.35 0.06926
Male (%) 87 77 0.127365
BMI kg/m2 28.87±4.56 28.42±4.27 0.574937
Weight (Kg) 77.84±12.14 77.00±18.54 0.369687
Height (cm) 164.35±6.97 158.97±18.40 0.008105
HR (bpm) 73.9±12.28 80.72±13.31 0.002259
SBP(mmHg) 122.37±24.56 124.14±22.55 0.158772
Ischaemic heart disease(%) 100 100
Hypertension(%) 15 23 0.209274
COPD(%) 48 57 0.299849
Diabetes(%) 32 39 0.427626
Chronic kidney failure 37 39 0.699283
Creatinine 1.53±0.56 1.53±0.54 0.976749
III-IV NYHA (%) 58 89 0.001469
AICD/CRT-D(%) 28 34 0.638949
Ivabradine (%) 12 2 0.051003
ACE (%) 59 55 0.645563
ARB (%) 21 7 0.032010
Beta-blockers (%) 79 72 0.3681
Digoxin (%) 8 23 0.0088
Diuretics (%) 81 90 0.155369
NT-pro-BNP 1159.00±1447.28 1181.75±1507.064 0.977292
CRP 6.56±11.32 32.36±12.79 0.000867
LVEF(%) 38.61±11.59 35.11±12.67 0.19749
LVEDD (mm) 58.51±10.61 57.81±10.81 0.727871
LVESD (mm) 50.21±13.86 53.73±9.32 0.354087
E (cm/s) 76.79±28.95 107.20±35.62 0.000005
A (cm/s) 84.39±23.69 78.25±34.65 0.344733
E/A 1.59±0.82 2.25±0.88 0.000163
EDT (ms) 221.12±89.02 191.07±90.46 0.132104
E/E’ 13.71±5.32 18.47±8.19 0.000259
S (cm/s) 8.59±2.692 5.38±1.84 0.532207
E’ (cm/s) 6.35±2.64 6.14±2.20 0.687242
IVCT (ms) 94.12±40.010 81.18±27.605 0.214355
ET (ms) 259.88±45.462 241.00±44.798 0.132284
IVRT (ms) 124.06±49.231 86.35±32.873 0.003923
St (ms) 354.00±44.824 322.18±62.542 0.020265
FT (ms) 379.37±121.081 317.94±87.617 0.054558
Dt (ms) 503.43±131.943 404.29±89.829 0.004705
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heart might contribute to the improvement in cardiac function
and subsequently improve the clinical outcomes of chronic
HF patients in treatment with atorvastatin or simvastatin.
Zhang et al. [31] demonstrated that atorvastatin treatment
was associated with reduced all-cause mortality and
readmission rate for HF, and the superiority of statin therapy
was significant in chronic HF patients younger than 65 years.
In previous works, statins appear to benefit patients with non-
ischaemic and ischaemic cardiomyopathy similarly [32]; our
results, however, seem to suggest a wider benefit of atorvastatin
therapy in patients with coronary heart disease. In fact, besides a
lower incidence of cardiac death, those receiving therapy with
atorvastatin also showed a lower incidence of ventricular ar-
rhythmias. Previous authors have already shown that non anti-
arrhythmic drugs, such as renin-angiotensin-aldosterone system
inhibitors, fish oil, and statins, can reduce the likelihood of
future ventricular tachycardia/ventricular fibrillation in patients
with coronary artery disease or congestive HF [33]. Desai et al.
[34] similarly found that statins may reduce appropriate
cardioverter-defibrillator shocks and mortality in 209 patients
with HF treated with combined cardiac resynchronisation ther-
apy and implantable cardioverter-defibrillator therapy.
Possible mechanisms by which statins exert their positive
effect are not completely known. In our study, statin admin-
istration was related to a better LV performance at TDI.
There is evidence that abnormal parameters by TDI may
identify subjects at risk for adverse events in major cardiac
diseases, such as HF [35]. In particular, patients with re-
duced S’ or E’ values of <3 cm/s have a very poor progno-
sis. In HF and after myocardial infarction, non-invasive
assessment of LV diastolic pressure by trans-mitral to mitral
annular early diastolic velocity ratio (E/E’) is a strong prog-
nosticator, especially when E/E’ is ≥15.
A few authors have assessed the effect of statin therapy on
LV function by TDI; previous authors showed that in coronary
artery disease patients, when compared with the baseline, S’
and E’ increased significantly after the therapy in the atorva-
statin group [36]. In our study, HF patients receiving statins
were characterised by lower values of E/A and E/E’ and
higher values of EDT; furthermore lower values of E/E’ ratio
and higher EDT, suggesting minor grade of diastolic dysfunc-
tion, were shown in ischaemic CHF patients receiving therapy
with statins. Few authors have evaluated these intervals in
CHF patients; Reant et al. [3], showed that St intervals can be
used for detecting alterations in LV systolic function. Cheng et
al. determined the cutoff values for ET in predicting high N-
terminal pro-brain natriuretic peptide levels [4]. Time intervals
assessed by TDI, ET and St may be helpful in predicting the
risk of rehospitalisation in subjects with chronic HF [37].
Recently we showed higher values of ET and St in
ischaemic CHF patients receiving therapy with statins than
controls [19]. So, lower values of St intervals, as ET, in
patients not treated with statins, might also suggest a higher
grade of LV diastolic dysfunction characterising these pa-
tients [38]. These previous data [19] seem to be confirmed
in CHF patents with systolic dysfunction in atorvastatin
therapy. We were also able to show, in atorvastatin therapy
patients, a lower grade of diastolic dysfunction than in
controls by conventional Doppler (E/A and EDT) and TDI
(E/E’) and longer systolic intervals (St).
Other possible mechanisms by which statins exert their
positive effect may be hypothesised in non-lipid related or
pleiotropic effects. Statins may inhibit or reverse myocardial
remodelling [39–41], inhibit inflammation in HF, improve
endothelial function [11, 42, 43] and restore autonomic
nervous system balance [17]. In fact, Tousoulis et al. [44]
recently demonstrated that 4 weeks of administration of
atorvastatin 40 mg/d in patients with ischaemic HF im-
proved endothelial function and arterial stiffness, indices
of left ventricular remodelling and adhesion molecules.
The effects of atorvastatin on indices of arterial function
were dose dependent because no significant changes were
found after treatment with atorvastatin 10 mg/d.
Limitations
These are preliminary data coming from a non-randomised
observational registry with a limited number of patients en-
rolled. Statin administration only depended on clinician judge-
ment. Further randomised trials are needed to confirm these
results.
Conclusions
CHF outpatients with LVEF ≤40 %, receiving atorvastatin
treatment, showed fewer cardiac deaths and a better LV
performance assessed by TDI.
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